IDEAYA Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net loss | $(112,961) | $(58,655) | $(49,762) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation and amortization | 2,476 | 2,101 | 1,725 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | (11,553) | (695) | 1,834 |
| Stock-based compensation | 18,489 | 11,629 | 8,237 |
| Amortization of right of use assets | 1,532 | 1,414 | 1,307 |
| Changes in assets and liabilities | |||
| Accounts receivable | 193 | 892 | 774 |
| Prepaid expenses and other assets | (2,045) | (2,119) | (189) |
| Accounts payable | 2,635 | 1,864 | 1,166 |
| Accrued and other liabilities | 1,635 | 4,572 | 4,212 |
| Contract liabilities | (13,753) | (46,479) | (23,541) |
| Lease liabilities | (1,872) | (1,699) | (1,542) |
| Net cash used in operating activities | (115,224) | (87,175) | (55,779) |
| Cash flows from investing activities | |||
| Purchases of property and equipment, net | (2,368) | (3,443) | (2,644) |
| Purchases of marketable securities | (595,980) | (255,808) | (314,996) |
| Maturities of marketable securities | 439,892 | 225,847 | 243,956 |
| Sales of marketable securities | - | - | 4,018 |
| Net cash used in investing activities | (158,456) | (33,404) | (69,666) |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 281,165 | 86,105 | 85,990 |
| Proceeds from issuances of pre-funded warrants | 42,182 | — | — |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | 28,598 | 8,857 | 57,263 |
| Proceeds from exercise of common stock options, net of repurchases | 9,559 | 1,448 | 1,504 |
| Proceeds from ESPP purchases | 1,213 | 755 | 697 |
| Net cash provided by financing activities | 362,717 | 97,165 | 145,454 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 89,037 | (23,414) | 20,009 |
| Cash, cash equivalents and restricted cash | |||
| Cash, cash equivalents and restricted cash, at beginning of period | 68,738 | 92,152 | 72,143 |
| Cash, cash equivalents and restricted cash, at end of period | $157,775 | $68,738 | $92,152 |
| Reconciliation of cash, cash equivalents and restricted cash | |||
| Cash and cash equivalents | $157,018 | $68,632 | $92,046 |
| Restricted cash | $757 | $106 | $106 |
| Cash, cash equivalents and restricted cash | $157,775 | $68,738 | $92,152 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for income taxes | $— | $— | $4 |
| Cash paid for interest | $69 | $60 | $71 |
| Supplemental non-cash investing and financing activities: | |||
| Vesting of early exercised options and restricted stock | $— | $— | $24 |
| Purchases of property and equipment in accounts payable and accrued liabilities | $147 | $384 | $92 |
| Right-of-use asset obtained in exchange for a new operating lease liability | $1,294 | $— | $— |
| Unpaid offering costs | $43 | $39 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.